- A team of scientists, led by an Indian, has reportedly developed a plant protein-based drug for treatment of all infectious diseases, including Malaria, AIDs and Ebola.
The drug, which is still under clinical trial, could eventually be 'a single vaccine adjuvant shot to treat multiple infectious diseases.'
"We are developing peptide-based vaccine adjuvants that boost the immune system against infectious diseases," Dr. Rajagopal Appavu, a scientist at the Department of Pharmacology and Toxicology, University of Texas and lead author of the paper 'Enhancing the Magnitude of Antibody Responses through Biomaterial Stereochemistry' was quoted by the Indian Science Journal (ISJ), as saying.
"All the peptides reported have toxicity under the acceptable limit," he added
D-peptides or D-proteins are present in plant cells and therefore, have no adverse effect on human physiology. The source of D-peptides are Pasture Grass (Phalaris tuberosa), Sunflower (Helianthus Annuus), Beechnuts, Wheat (Triticum Asetivum) and Lentil (Ervum Lens).
Drugs currently licensed for human use are aluminum-based salts, or alum or alum-MPL (alum in combination with monophosphoryl lipid A). Many vaccines under development are chemically heterogeneous mixtures of plant or pathogen-derived products, formulations of mineral salts or emulsions, which have associated toxicity. On the other hand, the current experiments by the team would pave the way for D-peptide -based natural nano-fibre vaccine adjuvants that can be taken orally and is effective for a longer period of time.
"To the best of our knowledge, we are the first to design D-peptide vaccine adjuvants for infectious diseases," said Dr. Rajgopal.
Dr. Rajagopal said, self-assembling peptides composed of D-amino acids are strong immune adjuvants and can be used as a design tool to program adaptive immune responses for vaccine development.
These vaccines can be antibodies to identify and neutralize pathogens such as bacteria and virus, that causes infectious diseases, AIDs and Ebola, explained Dr. Rajagopal.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
